1. The Impact of the Fecal Microbiome on Cancer Immunotherapy

   • Afaf E. G. Osman
   • Jason J. Luke

   Current Opinion 02 January 2019 Pages: 1 - 7

2. Current Ebola Virus Vaccine Progress

   • Andrea Marzi
   • Chad E. Mire

   Leading Article 02 January 2019 Pages: 9 - 14

3. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases

   • Anniina T. Virtanen
   • Teemu Haikarainen
   • Olli Silvennoinen

   Review Article Open access 30 January 2019 Pages: 15 - 32

   

4. Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies

   • Paula J. Busse
   • Henriette Farkas
   • Marc A. Riedl

   Review Article Open access 12 December 2018 Pages: 33 - 43

   

5. Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities

   • Bhagirathbhai R. Dholaria
   • Christina A. Bachmeier
   • Frederick Locke

   Review Article 17 December 2018 Pages: 45 - 60

6. Monoclonal Antibodies for Multiple Sclerosis: An Update

   • Jonas Graf
   • Orhan Aktas
   • Hans-Peter Hartung

   Review Article 02 January 2019 Pages: 61 - 78

7. Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial

   • Chang-Hee Suh
   • Dae Hyun Yoo
   • Sung Young Lee

   Original Research Article Open access 05 February 2019 Pages: 79 - 91

   

8. A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects

   • Tan Zhang
   • Guihong Chen
   • Yi Fang

   Original Research Article 03 December 2018 Pages: 93 - 100

   

9. Comparison of the Pharmacokinetic–Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers

   • Seokuee Kim
   • Taegon Hong
   • Jung-Ryul Kim

   Original Research Article Open access 01 December 2018 Pages: 101 - 112

   

10. FKB327: An Adalimumab Biosimilar

    • Zaina T. Al-Salama

    Adis Biosimilar Brief 02 February 2019 Pages: 113 - 116

    

11. Pegfilgrastim-jmdb/MYL-1401H: A Pegfilgrastim Biosimilar

    • Sheridan M. Hoy

    Adis Biosimilar Brief 30 January 2019 Pages: 117 - 120

    

12. Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?”

    • Sarfaraz K. Niazi

    Letter to the Editor 02 January 2019 Pages: 121 - 123